Abstract 1404P
Background
Combination of anti-PD1 inhibitor with chemoradiotherapy (CRT) has been shown to improve the survival of patients with locally advanced esophageal squamous cell carcinoma (ESCC). This study specifically aims to identify circulating cytokines as biomarkers for predicting treatment response, survival, and immune-related toxicities.
Methods
Patients with locally advanced ESCC from two phase II clinical trials (EC-CRT-001 and NEOCRTEC1901) were pooled for analysis. All patients received CRT in combination with toripalimab, an anti-PD1 inhibitor. We longitudinally profiled 19 cytokines in the plasma before (pre), during, and after (post) CRT. The associations between cytokine levels and treatment response or immune-related toxicity were examined using the Wilcoxon test. Their correlations with overall survival (OS) and progression-free survival (PFS) were assessed through univariate and multivariate Cox analyses.
Results
A total of 81 patients were included, and 243 plasma samples were analyzed. Multivariate analyses indicated that pre-treatment levels of IL-8 and post-treatment levels of Granzyme B were independent prognostic markers for OS (p<0.05). Post-CRT levels of IL-10 were identified as independent prognostic markers for PFS (p<0.05). Subgroup analyses revealed correlations between pre- and during-CRT levels of IL-8, and post-CRT levels of IL-13 and IL-10 with a complete clinical response in the EC-CRT-001 group. Additionally, pre-CRT IL-8 and post-CRT CCL5 levels were associated with immune-related toxicities.
Conclusions
Circulating cytokines, particularly IL-8, serve as significant biomarkers for predicting response, survival, and immune-related toxicities in locally advanced ESCC patients undergoing combined chemoradiotherapy and toripalimab treatment.
Clinical trial identification
NCT04005170; NCT04006041.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
951P - CA19-9-related macrophage polarization has prognostic value in patients with HCC after immune checkpoint inhibitor treatment
Presenter: Meiyan Zhu
Session: Poster session 17
952P - Comprehensive analysis of cytokines and PDL1 before and after administration of atezolizumab and bevasizumab in patients with HCC
Presenter: Kyoji Ito
Session: Poster session 17
953P - Vessels that encapsulate tumor clusters (VETC): A promising prognostic predictor for patients with hepatocellular carcinoma treated with tyrosine kinase inhibitor and immunotherapy combinations
Presenter: Yanjiang Yin
Session: Poster session 17
954P - Evaluation of antigen-specific CD8 T cell responses to predict efficacy of atezolizumab and bevacizumab treatment in hepatocellular carcinoma
Presenter: Angélique Vienot
Session: Poster session 17
957P - Modelling immune-mediated cytotoxicity for HCC with patient-derived organoid co-culture platform
Presenter: Tsz Tung Kwong
Session: Poster session 17
958P - Utilizing personalized tumor-specific methylation haplotypes of circulating tumor DNA for monitoring minimal residual disease in hepatocellular carcinoma patients after curative resection
Presenter: Xinrong Yang
Session: Poster session 17
959P - Machine learning-based MRI radiomics predicts overall survival of unresectable hepatocellular carcinoma undergoing transarterial chemoembolization plus PD-(L)1 inhibitors and molecular targeted therapy
Presenter: Bin-Yan Zhong
Session: Poster session 17
960P - Development and validation of a novel digital PCR assay targeting circulating tumor DNA methylation biomarkers for hepatocellular carcinoma screening
Presenter: Hee-Jung Wang
Session: Poster session 17